Clinical approach of hereditary cancer in gynecology.
- Author:
Chae Hyeong LEE
1
;
Ju Won ROH
Author Information
1. Department of Obstetrics and Gynecology, Dongguk University Ilsan Hospital, College of Medicine, Dongguk University, Gyeonggi, Korea. rohjuwon@duih.org
- Publication Type:Review
- Keywords:
Hereditary cancer syndrome;
Hereditary breast/ovarian cancer syndrome (HBOC);
Hereditary non-polyposis colorectal cancer (HNPCC);
Li-Fraumeni syndrome;
Cowden syndrome
- MeSH:
Colorectal Neoplasms;
Female;
Genetic Testing;
Gynecology;
Hamartoma Syndrome, Multiple;
Humans;
Li-Fraumeni Syndrome;
Mass Screening;
Molecular Biology;
Neoplastic Syndromes, Hereditary;
Parents;
Penetrance;
Pliability;
Risk Factors;
Risk Reduction Behavior
- From:Korean Journal of Obstetrics and Gynecology
2009;52(1):1-16
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Hereditary cancer syndrome is a genetic condition that causes and increases the risk for specific type of cancers. Recent advances in genetics have identified a number of genes associated with inherited susceptibility to cancer, and this rapid development of knowledge about cancer genetics have implications for all aspects of cancer management, including prevention, screening, and treatment. Hereditary patterns of cancer are often characterized by early age at onset, high penetrance, bilaterality in paired organs, vertical transmission through either parent, and an association with other types of tumors. Most representative hereditary cancer syndromes in gynecologic field are hereditary breast/ovarian cancer syndrome (HBOC), hereditary non-polyposis colorectal cancer (HNPCC), Li-Fraumeni syndrome, and Cowden syndrome. Several familial mutations of specific genes, such as BRCA1, 2, TP53, PTEN, MMR, CHEK2, are linked to hereditary cancer syndrome, which are responsible for hereditary gynecologic cancers. It would be very important for gynecologic doctors to know the inclusion criteria for the genetic assessment, taking family history, clinical evaluation, genetic testing, screening guideline and risk reduction strategies for women with hereditary high risk factor. The morbidity and mortality of gynecologic malignancies related to these syndromes could be reduced by the adequate clinical approach, although recent guidelines were developed with an acute awareness of the preliminary nature of much of our knowledge regarding the clinical application of the rapidly emerging field of molecular genetics, and with an appreciation for the need for flexibility when applying these guidelines to individual families.
